カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の二価ヒトパピローマウイルスワクチン市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Bivalent Human Papillomavirus Vaccine Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19179）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19179
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：95
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の二価ヒトパピローマウイルスワクチン市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

二価ヒトパピローマウイルスワクチン市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の二価ヒトパピローマウイルスワクチンの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

二価ヒトパピローマウイルスワクチン市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・HPV16、HPV18

用途別セグメントは次のように区分されます。
・9～16歳、16～20歳、20～26歳、26～45歳

世界の二価ヒトパピローマウイルスワクチン市場の主要な市場プレーヤーは以下のとおりです。
・Merck & Co., Inc.、GSK、INNOVAX、ZSSW、HUMANWELL HEALTHCARE、WALVAX、Serum Institute of India

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、二価ヒトパピローマウイルスワクチン製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な二価ヒトパピローマウイルスワクチンメーカーの企業概要、2019年～2022年までの二価ヒトパピローマウイルスワクチンの価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な二価ヒトパピローマウイルスワクチンメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別二価ヒトパピローマウイルスワクチンの販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの二価ヒトパピローマウイルスワクチンの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での二価ヒトパピローマウイルスワクチン市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および二価ヒトパピローマウイルスワクチンの産業チェーンを掲載しています。
・第13、14、15章では、二価ヒトパピローマウイルスワクチンの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 二価ヒトパピローマウイルスワクチンの概要
- 種類別分析（2017年vs2021年vs2028年）：HPV16、HPV18
- 用途別分析（2017年vs2021年vs2028年）：9～16歳、16～20歳、20～26歳、26～45歳
- 世界の二価ヒトパピローマウイルスワクチン市場規模・予測
- 世界の二価ヒトパピローマウイルスワクチン生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Merck & Co., Inc.、GSK、INNOVAX、ZSSW、HUMANWELL HEALTHCARE、WALVAX、Serum Institute of India
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：HPV16、HPV18
・用途別分析2017年-2028年：9～16歳、16～20歳、20～26歳、26～45歳
・二価ヒトパピローマウイルスワクチンの北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・二価ヒトパピローマウイルスワクチンのヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・二価ヒトパピローマウイルスワクチンのアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・二価ヒトパピローマウイルスワクチンの南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・二価ヒトパピローマウイルスワクチンの中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Bivalent Human Papillomavirus Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Bivalent Human Papillomavirus Vaccine market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. 9-16 Years Old accounting for % of the Bivalent Human Papillomavirus Vaccine global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While HPV16 segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Bivalent Human Papillomavirus Vaccine include Merck & Co., Inc., GSK, INNOVAX, ZSSW, and HUMANWELL HEALTHCARE, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Bivalent Human Papillomavirus Vaccine market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
HPV16
HPV18
Market segment by Application can be divided into
9-16 Years Old
16-20 Years Old
20-26 Years Old
26-45 Years Old
The key market players for global Bivalent Human Papillomavirus Vaccine market are listed below:
Merck & Co., Inc.
GSK
INNOVAX
ZSSW
HUMANWELL HEALTHCARE
WALVAX
Serum Institute of India
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Bivalent Human Papillomavirus Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Bivalent Human Papillomavirus Vaccine, with price, sales, revenue and global market share of Bivalent Human Papillomavirus Vaccine from 2019 to 2022.
Chapter 3, the Bivalent Human Papillomavirus Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Bivalent Human Papillomavirus Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Bivalent Human Papillomavirus Vaccine market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Bivalent Human Papillomavirus Vaccine.
Chapter 13, 14, and 15, to describe Bivalent Human Papillomavirus Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Bivalent Human Papillomavirus Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Bivalent Human Papillomavirus Vaccine Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 HPV16
1.2.3 HPV18
1.3 Market Analysis by Application
1.3.1 Overview: Global Bivalent Human Papillomavirus Vaccine Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 9-16 Years Old
1.3.3 16-20 Years Old
1.3.4 20-26 Years Old
1.3.5 26-45 Years Old
1.4 Global Bivalent Human Papillomavirus Vaccine Market Size & Forecast
1.4.1 Global Bivalent Human Papillomavirus Vaccine Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Bivalent Human Papillomavirus Vaccine Sales in Volume (2017-2028)
1.4.3 Global Bivalent Human Papillomavirus Vaccine Price (2017-2028)
1.5 Global Bivalent Human Papillomavirus Vaccine Production Capacity Analysis
1.5.1 Global Bivalent Human Papillomavirus Vaccine Total Production Capacity (2017-2028)
1.5.2 Global Bivalent Human Papillomavirus Vaccine Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Bivalent Human Papillomavirus Vaccine Market Drivers
1.6.2 Bivalent Human Papillomavirus Vaccine Market Restraints
1.6.3 Bivalent Human Papillomavirus Vaccine Trends Analysis
2 Manufacturers Profiles
2.1 Merck & Co., Inc.
2.1.1 Merck & Co., Inc. Details
2.1.2 Merck & Co., Inc. Major Business
2.1.3 Merck & Co., Inc. Bivalent Human Papillomavirus Vaccine Product and Services
2.1.4 Merck & Co., Inc. Bivalent Human Papillomavirus Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 GSK
2.2.1 GSK Details
2.2.2 GSK Major Business
2.2.3 GSK Bivalent Human Papillomavirus Vaccine Product and Services
2.2.4 GSK Bivalent Human Papillomavirus Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 INNOVAX
2.3.1 INNOVAX Details
2.3.2 INNOVAX Major Business
2.3.3 INNOVAX Bivalent Human Papillomavirus Vaccine Product and Services
2.3.4 INNOVAX Bivalent Human Papillomavirus Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 ZSSW
2.4.1 ZSSW Details
2.4.2 ZSSW Major Business
2.4.3 ZSSW Bivalent Human Papillomavirus Vaccine Product and Services
2.4.4 ZSSW Bivalent Human Papillomavirus Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 HUMANWELL HEALTHCARE
2.5.1 HUMANWELL HEALTHCARE Details
2.5.2 HUMANWELL HEALTHCARE Major Business
2.5.3 HUMANWELL HEALTHCARE Bivalent Human Papillomavirus Vaccine Product and Services
2.5.4 HUMANWELL HEALTHCARE Bivalent Human Papillomavirus Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 WALVAX
2.6.1 WALVAX Details
2.6.2 WALVAX Major Business
2.6.3 WALVAX Bivalent Human Papillomavirus Vaccine Product and Services
2.6.4 WALVAX Bivalent Human Papillomavirus Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Serum Institute of India
2.7.1 Serum Institute of India Details
2.7.2 Serum Institute of India Major Business
2.7.3 Serum Institute of India Bivalent Human Papillomavirus Vaccine Product and Services
2.7.4 Serum Institute of India Bivalent Human Papillomavirus Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Bivalent Human Papillomavirus Vaccine Breakdown Data by Manufacturer
3.1 Global Bivalent Human Papillomavirus Vaccine Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Bivalent Human Papillomavirus Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Bivalent Human Papillomavirus Vaccine
3.4 Market Concentration Rate
3.4.1 Top 3 Bivalent Human Papillomavirus Vaccine Manufacturer Market Share in 2021
3.4.2 Top 6 Bivalent Human Papillomavirus Vaccine Manufacturer Market Share in 2021
3.5 Global Bivalent Human Papillomavirus Vaccine Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Bivalent Human Papillomavirus Vaccine Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Bivalent Human Papillomavirus Vaccine Market Size by Region
4.1.1 Global Bivalent Human Papillomavirus Vaccine Sales in Volume by Region (2017-2028)
4.1.2 Global Bivalent Human Papillomavirus Vaccine Revenue by Region (2017-2028)
4.2 North America Bivalent Human Papillomavirus Vaccine Revenue (2017-2028)
4.3 Europe Bivalent Human Papillomavirus Vaccine Revenue (2017-2028)
4.4 Asia-Pacific Bivalent Human Papillomavirus Vaccine Revenue (2017-2028)
4.5 South America Bivalent Human Papillomavirus Vaccine Revenue (2017-2028)
4.6 Middle East and Africa Bivalent Human Papillomavirus Vaccine Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Bivalent Human Papillomavirus Vaccine Sales in Volume by Type (2017-2028)
5.2 Global Bivalent Human Papillomavirus Vaccine Revenue by Type (2017-2028)
5.3 Global Bivalent Human Papillomavirus Vaccine Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Bivalent Human Papillomavirus Vaccine Sales in Volume by Application (2017-2028)
6.2 Global Bivalent Human Papillomavirus Vaccine Revenue by Application (2017-2028)
6.3 Global Bivalent Human Papillomavirus Vaccine Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Bivalent Human Papillomavirus Vaccine Sales by Type (2017-2028)
7.2 North America Bivalent Human Papillomavirus Vaccine Sales by Application (2017-2028)
7.3 North America Bivalent Human Papillomavirus Vaccine Market Size by Country
7.3.1 North America Bivalent Human Papillomavirus Vaccine Sales in Volume by Country (2017-2028)
7.3.2 North America Bivalent Human Papillomavirus Vaccine Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Bivalent Human Papillomavirus Vaccine Sales by Type (2017-2028)
8.2 Europe Bivalent Human Papillomavirus Vaccine Sales by Application (2017-2028)
8.3 Europe Bivalent Human Papillomavirus Vaccine Market Size by Country
8.3.1 Europe Bivalent Human Papillomavirus Vaccine Sales in Volume by Country (2017-2028)
8.3.2 Europe Bivalent Human Papillomavirus Vaccine Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales by Type (2017-2028)
9.2 Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales by Application (2017-2028)
9.3 Asia-Pacific Bivalent Human Papillomavirus Vaccine Market Size by Region
9.3.1 Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Bivalent Human Papillomavirus Vaccine Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Bivalent Human Papillomavirus Vaccine Sales by Type (2017-2028)
10.2 South America Bivalent Human Papillomavirus Vaccine Sales by Application (2017-2028)
10.3 South America Bivalent Human Papillomavirus Vaccine Market Size by Country
10.3.1 South America Bivalent Human Papillomavirus Vaccine Sales in Volume by Country (2017-2028)
10.3.2 South America Bivalent Human Papillomavirus Vaccine Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales by Type (2017-2028)
11.2 Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales by Application (2017-2028)
11.3 Middle East & Africa Bivalent Human Papillomavirus Vaccine Market Size by Country
11.3.1 Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Bivalent Human Papillomavirus Vaccine Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Bivalent Human Papillomavirus Vaccine and Key Manufacturers
12.2 Manufacturing Costs Percentage of Bivalent Human Papillomavirus Vaccine
12.3 Bivalent Human Papillomavirus Vaccine Production Process
12.4 Bivalent Human Papillomavirus Vaccine Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Bivalent Human Papillomavirus Vaccine Typical Distributors
13.3 Bivalent Human Papillomavirus Vaccine Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Bivalent Human Papillomavirus Vaccine Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Bivalent Human Papillomavirus Vaccine Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 4. Merck & Co., Inc. Major Business
Table 5. Merck & Co., Inc. Bivalent Human Papillomavirus Vaccine Product and Services
Table 6. Merck & Co., Inc. Bivalent Human Papillomavirus Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. GSK Basic Information, Manufacturing Base and Competitors
Table 8. GSK Major Business
Table 9. GSK Bivalent Human Papillomavirus Vaccine Product and Services
Table 10. GSK Bivalent Human Papillomavirus Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. INNOVAX Basic Information, Manufacturing Base and Competitors
Table 12. INNOVAX Major Business
Table 13. INNOVAX Bivalent Human Papillomavirus Vaccine Product and Services
Table 14. INNOVAX Bivalent Human Papillomavirus Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. ZSSW Basic Information, Manufacturing Base and Competitors
Table 16. ZSSW Major Business
Table 17. ZSSW Bivalent Human Papillomavirus Vaccine Product and Services
Table 18. ZSSW Bivalent Human Papillomavirus Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. HUMANWELL HEALTHCARE Basic Information, Manufacturing Base and Competitors
Table 20. HUMANWELL HEALTHCARE Major Business
Table 21. HUMANWELL HEALTHCARE Bivalent Human Papillomavirus Vaccine Product and Services
Table 22. HUMANWELL HEALTHCARE Bivalent Human Papillomavirus Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. WALVAX Basic Information, Manufacturing Base and Competitors
Table 24. WALVAX Major Business
Table 25. WALVAX Bivalent Human Papillomavirus Vaccine Product and Services
Table 26. WALVAX Bivalent Human Papillomavirus Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Serum Institute of India Basic Information, Manufacturing Base and Competitors
Table 28. Serum Institute of India Major Business
Table 29. Serum Institute of India Bivalent Human Papillomavirus Vaccine Product and Services
Table 30. Serum Institute of India Bivalent Human Papillomavirus Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Global Bivalent Human Papillomavirus Vaccine Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 32. Global Bivalent Human Papillomavirus Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 33. Market Position of Manufacturers in Bivalent Human Papillomavirus Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 34. Global Bivalent Human Papillomavirus Vaccine Production Capacity by Company, (K Units): 2020 VS 2021
Table 35. Head Office and Bivalent Human Papillomavirus Vaccine Production Site of Key Manufacturer
Table 36. Bivalent Human Papillomavirus Vaccine New Entrant and Capacity Expansion Plans
Table 37. Bivalent Human Papillomavirus Vaccine Mergers & Acquisitions in the Past Five Years
Table 38. Global Bivalent Human Papillomavirus Vaccine Sales by Region (2017-2022) & (K Units)
Table 39. Global Bivalent Human Papillomavirus Vaccine Sales by Region (2023-2028) & (K Units)
Table 40. Global Bivalent Human Papillomavirus Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 41. Global Bivalent Human Papillomavirus Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 42. Global Bivalent Human Papillomavirus Vaccine Sales by Type (2017-2022) & (K Units)
Table 43. Global Bivalent Human Papillomavirus Vaccine Sales by Type (2023-2028) & (K Units)
Table 44. Global Bivalent Human Papillomavirus Vaccine Revenue by Type (2017-2022) & (USD Million)
Table 45. Global Bivalent Human Papillomavirus Vaccine Revenue by Type (2023-2028) & (USD Million)
Table 46. Global Bivalent Human Papillomavirus Vaccine Price by Type (2017-2022) & (US$/Unit)
Table 47. Global Bivalent Human Papillomavirus Vaccine Price by Type (2023-2028) & (US$/Unit)
Table 48. Global Bivalent Human Papillomavirus Vaccine Sales by Application (2017-2022) & (K Units)
Table 49. Global Bivalent Human Papillomavirus Vaccine Sales by Application (2023-2028) & (K Units)
Table 50. Global Bivalent Human Papillomavirus Vaccine Revenue by Application (2017-2022) & (USD Million)
Table 51. Global Bivalent Human Papillomavirus Vaccine Revenue by Application (2023-2028) & (USD Million)
Table 52. Global Bivalent Human Papillomavirus Vaccine Price by Application (2017-2022) & (US$/Unit)
Table 53. Global Bivalent Human Papillomavirus Vaccine Price by Application (2023-2028) & (US$/Unit)
Table 54. North America Bivalent Human Papillomavirus Vaccine Sales by Country (2017-2022) & (K Units)
Table 55. North America Bivalent Human Papillomavirus Vaccine Sales by Country (2023-2028) & (K Units)
Table 56. North America Bivalent Human Papillomavirus Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 57. North America Bivalent Human Papillomavirus Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 58. North America Bivalent Human Papillomavirus Vaccine Sales by Type (2017-2022) & (K Units)
Table 59. North America Bivalent Human Papillomavirus Vaccine Sales by Type (2023-2028) & (K Units)
Table 60. North America Bivalent Human Papillomavirus Vaccine Sales by Application (2017-2022) & (K Units)
Table 61. North America Bivalent Human Papillomavirus Vaccine Sales by Application (2023-2028) & (K Units)
Table 62. Europe Bivalent Human Papillomavirus Vaccine Sales by Country (2017-2022) & (K Units)
Table 63. Europe Bivalent Human Papillomavirus Vaccine Sales by Country (2023-2028) & (K Units)
Table 64. Europe Bivalent Human Papillomavirus Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 65. Europe Bivalent Human Papillomavirus Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 66. Europe Bivalent Human Papillomavirus Vaccine Sales by Type (2017-2022) & (K Units)
Table 67. Europe Bivalent Human Papillomavirus Vaccine Sales by Type (2023-2028) & (K Units)
Table 68. Europe Bivalent Human Papillomavirus Vaccine Sales by Application (2017-2022) & (K Units)
Table 69. Europe Bivalent Human Papillomavirus Vaccine Sales by Application (2023-2028) & (K Units)
Table 70. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales by Region (2017-2022) & (K Units)
Table 71. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales by Region (2023-2028) & (K Units)
Table 72. Asia-Pacific Bivalent Human Papillomavirus Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 73. Asia-Pacific Bivalent Human Papillomavirus Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 74. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales by Type (2017-2022) & (K Units)
Table 75. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales by Type (2023-2028) & (K Units)
Table 76. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales by Application (2017-2022) & (K Units)
Table 77. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales by Application (2023-2028) & (K Units)
Table 78. South America Bivalent Human Papillomavirus Vaccine Sales by Country (2017-2022) & (K Units)
Table 79. South America Bivalent Human Papillomavirus Vaccine Sales by Country (2023-2028) & (K Units)
Table 80. South America Bivalent Human Papillomavirus Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 81. South America Bivalent Human Papillomavirus Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 82. South America Bivalent Human Papillomavirus Vaccine Sales by Type (2017-2022) & (K Units)
Table 83. South America Bivalent Human Papillomavirus Vaccine Sales by Type (2023-2028) & (K Units)
Table 84. South America Bivalent Human Papillomavirus Vaccine Sales by Application (2017-2022) & (K Units)
Table 85. South America Bivalent Human Papillomavirus Vaccine Sales by Application (2023-2028) & (K Units)
Table 86. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales by Region (2017-2022) & (K Units)
Table 87. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales by Region (2023-2028) & (K Units)
Table 88. Middle East & Africa Bivalent Human Papillomavirus Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 89. Middle East & Africa Bivalent Human Papillomavirus Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 90. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales by Type (2017-2022) & (K Units)
Table 91. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales by Type (2023-2028) & (K Units)
Table 92. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales by Application (2017-2022) & (K Units)
Table 93. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales by Application (2023-2028) & (K Units)
Table 94. Bivalent Human Papillomavirus Vaccine Raw Material
Table 95. Key Manufacturers of Bivalent Human Papillomavirus Vaccine Raw Materials
Table 96. Direct Channel Pros & Cons
Table 97. Indirect Channel Pros & Cons
Table 98. Bivalent Human Papillomavirus Vaccine Typical Distributors
Table 99. Bivalent Human Papillomavirus Vaccine Typical Customers
List of Figures
Figure 1. Bivalent Human Papillomavirus Vaccine Picture
Figure 2. Global Bivalent Human Papillomavirus Vaccine Revenue Market Share by Type in 2021
Figure 3. HPV16
Figure 4. HPV18
Figure 5. Global Bivalent Human Papillomavirus Vaccine Revenue Market Share by Application in 2021
Figure 6. 9-16 Years Old
Figure 7. 16-20 Years Old
Figure 8. 20-26 Years Old
Figure 9. 26-45 Years Old
Figure 10. Global Bivalent Human Papillomavirus Vaccine Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 11. Global Bivalent Human Papillomavirus Vaccine Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Bivalent Human Papillomavirus Vaccine Sales (2017-2028) & (K Units)
Figure 13. Global Bivalent Human Papillomavirus Vaccine Price (2017-2028) & (US$/Unit)
Figure 14. Global Bivalent Human Papillomavirus Vaccine Production Capacity (2017-2028) & (K Units)
Figure 15. Global Bivalent Human Papillomavirus Vaccine Production Capacity by Geographic Region: 2022 VS 2028
Figure 16. Bivalent Human Papillomavirus Vaccine Market Drivers
Figure 17. Bivalent Human Papillomavirus Vaccine Market Restraints
Figure 18. Bivalent Human Papillomavirus Vaccine Market Trends
Figure 19. Global Bivalent Human Papillomavirus Vaccine Sales Market Share by Manufacturer in 2021
Figure 20. Global Bivalent Human Papillomavirus Vaccine Revenue Market Share by Manufacturer in 2021
Figure 21. Bivalent Human Papillomavirus Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 22. Top 3 Bivalent Human Papillomavirus Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 23. Top 6 Bivalent Human Papillomavirus Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 24. Global Bivalent Human Papillomavirus Vaccine Sales Market Share by Region (2017-2028)
Figure 25. Global Bivalent Human Papillomavirus Vaccine Revenue Market Share by Region (2017-2028)
Figure 26. North America Bivalent Human Papillomavirus Vaccine Revenue (2017-2028) & (USD Million)
Figure 27. Europe Bivalent Human Papillomavirus Vaccine Revenue (2017-2028) & (USD Million)
Figure 28. Asia-Pacific Bivalent Human Papillomavirus Vaccine Revenue (2017-2028) & (USD Million)
Figure 29. South America Bivalent Human Papillomavirus Vaccine Revenue (2017-2028) & (USD Million)
Figure 30. Middle East & Africa Bivalent Human Papillomavirus Vaccine Revenue (2017-2028) & (USD Million)
Figure 31. Global Bivalent Human Papillomavirus Vaccine Sales Market Share by Type (2017-2028)
Figure 32. Global Bivalent Human Papillomavirus Vaccine Revenue Market Share by Type (2017-2028)
Figure 33. Global Bivalent Human Papillomavirus Vaccine Price by Type (2017-2028) & (US$/Unit)
Figure 34. Global Bivalent Human Papillomavirus Vaccine Sales Market Share by Application (2017-2028)
Figure 35. Global Bivalent Human Papillomavirus Vaccine Revenue Market Share by Application (2017-2028)
Figure 36. Global Bivalent Human Papillomavirus Vaccine Price by Application (2017-2028) & (US$/Unit)
Figure 37. North America Bivalent Human Papillomavirus Vaccine Sales Market Share by Type (2017-2028)
Figure 38. North America Bivalent Human Papillomavirus Vaccine Sales Market Share by Application (2017-2028)
Figure 39. North America Bivalent Human Papillomavirus Vaccine Sales Market Share by Country (2017-2028)
Figure 40. North America Bivalent Human Papillomavirus Vaccine Revenue Market Share by Country (2017-2028)
Figure 41. United States Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Canada Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Mexico Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Europe Bivalent Human Papillomavirus Vaccine Sales Market Share by Type (2017-2028)
Figure 45. Europe Bivalent Human Papillomavirus Vaccine Sales Market Share by Application (2017-2028)
Figure 46. Europe Bivalent Human Papillomavirus Vaccine Sales Market Share by Country (2017-2028)
Figure 47. Europe Bivalent Human Papillomavirus Vaccine Revenue Market Share by Country (2017-2028)
Figure 48. Germany Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. France Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. United Kingdom Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Russia Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Italy Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales Market Share by Application (2017-2028)
Figure 55. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Bivalent Human Papillomavirus Vaccine Revenue Market Share by Region (2017-2028)
Figure 57. China Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Japan Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Korea Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. India Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Southeast Asia Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Australia Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South America Bivalent Human Papillomavirus Vaccine Sales Market Share by Type (2017-2028)
Figure 64. South America Bivalent Human Papillomavirus Vaccine Sales Market Share by Application (2017-2028)
Figure 65. South America Bivalent Human Papillomavirus Vaccine Sales Market Share by Country (2017-2028)
Figure 66. South America Bivalent Human Papillomavirus Vaccine Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales Market Share by Type (2017-2028)
Figure 70. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales Market Share by Application (2017-2028)
Figure 71. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales Market Share by Region (2017-2028)
Figure 72. Middle East & Africa Bivalent Human Papillomavirus Vaccine Revenue Market Share by Region (2017-2028)
Figure 73. Turkey Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Egypt Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South Africa Bivalent Human Papillomavirus Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Manufacturing Cost Structure Analysis of Bivalent Human Papillomavirus Vaccine in 2021
Figure 78. Manufacturing Process Analysis of Bivalent Human Papillomavirus Vaccine
Figure 79. Bivalent Human Papillomavirus Vaccine Industrial Chain
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 二価ヒトパピローマウイルスワクチンの世界市場2023年：HPV16、HPV18
  • 組換えヒトパピローマウイルス9価ワクチンのグローバル市場展望 2023年-2029年：女性、男性
  • ヒト注射用インフルエンザワクチンのグローバル市場展望 2023年-2029年：3価インフルエンザワクチン、4価インフルエンザワクチン
  • 人間用凍結乾燥狂犬病ワクチン（ヒト二倍体細胞）のグローバル市場展望 2023年-2029年：バイアル、充填済み
  • 世界のヒト凍結乾燥狂犬病ワクチン市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19179 )"世界の二価ヒトパピローマウイルスワクチン市場2022年：市場規模予測（～2028年）" (英文：Global Bivalent Human Papillomavirus Vaccine Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。